|MDACC Study No:||2013-0703 (clinicaltrials.gov NCT No: NCT02007044)|
|Title:||Randomized study of ibrutinib versus ibrutinib plus rituximab (i versus iR) in patients with relapsed chronic lymphocytic leukemia (CLL)|
|Principal Investigator:||Jan A. Burger|
|Treatment Agent:||Ibrutinib; Rituximab|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
ibrutinib and rituximab can help to control CLL better than ibrutinib alone.
The safety of these treatments will be also studied.